Although the combining actions of GLP-1 and glucagon could make oxyntomodulin an effective treatment in obesity, its short plasma half-life of around 12 min in humans has limited its use in clinical practice [35]. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.